Supplements as they should be

Cambridge Nutraceuticals Ltd develops and markets nutraceutical supplements under its brand FutureYou.  Sales are principally made directly to UK customers, although the business also has several overseas distributors, with Australia being a particularly significant market.

The company has a programme of observational and clinical studies at leading research centres.  As well as the completed trials, Cambridge Nutraceuticals has studies investigating the effect of its products on male fertility and subarachnoid haemorrhage and is beginning a new hospital-based study in a new clinical area.

The business’ objective is to supply supplements as they should be – in other words to develop and sell supplements which have clinical evidence of effectiveness and in particular that are proven to be bioavailable.

Cambridge Nutraceuticals’ business originated in the development, formulation and clinical trials of its first product, Ateronon, which is a bioavailable form of lycopene (found principally in tomatoes) that has been shown to be beneficial for cardiovascular health.

In its raw form, lycopene is not absorbed by the body.  Working with Nestle in Switzerland, we were able to develop a patented bioavailable form of lycopene by means of combination with soy lecithin (‘lactolycopene’).  Significant investment was then made in clinical trials of Ateronon for cardiovascular health.  Research was funded in 2008 and 2009 at Cambridge and the Saratova Cardiology Institute.  In 2014, the results of a 62-person double-blind placebo-controlled trial, funded and sponsored by Cambridge University Hospitals NHS Foundation Trust as well as the Wellcome Trust and the British Heart Foundation, published in a peer-reviewed journal, showed that Ateronon improved blood vessel flexibility by 53% in patients on statins.

The manufacturing partner for lactolycopene was selected to be Indena SpA, of Milan.  Manufacture of Ateronon is difficult, since lycopene oxidises rapidly.  Indena is one of Europe’s leading developers and manufacturers of botanical ingredients for pharmaceuticals and health supplements.  Like that of Cambridge Nutraceuticals, a particular focus of Indena’s research effort is on making botanical ingredients bioavailable.

Product research and development supported by a high profile medical board

Our medical advisory board includes some of the worlds leading scientists and doctors, including Professor Alf Lindberg MD, PhD, secretary of the Nobel Prize Committee for Physiology and Medicine, and Peter Kirkpatrick - FRCS (SN) FMedSci, a senior specialist neurosurgeon at Addenbrooke's hospital, a world class centre of medical expertise.